Table of contents
- Overview of the clinical research
- Study design and phase
- Who can participate
- What the trials measure
- Trial summary
- Important patient terms
Overview of the clinical research
The available trial is studying AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE in people with transfusion-dependent beta-thalassemia.[1] The brief study goal is to evaluate clinical efficacy in terms of transfusion independence in pediatric and adult patients.[1]
This research is focused on whether the treatment can help patients go without regular red blood cell transfusions.[1] The trial is described as a gene therapy study and is being run as an interventional clinical study.[1]
Study design and phase
The study is a single arm, open label, multicenter, single-dose trial.[1] Single arm means there is no separate comparison group listed in the provided data, and open label means both the study team and participants know what is being given.[1]
The trial is in Phase 2 and has an authorised status.[1] Phase 2 studies usually look more closely at whether a treatment works while continuing to monitor safety, and this matches the trial’s stated aim to evaluate efficacy and safety.[1]
Who can participate
The target population is people with transfusion-dependent beta-thalassemia, including both pediatric and adult patients.[1] The data provided do not list more detailed inclusion or exclusion rules, so only this broad group can be confirmed from the source.[1]
Beta-thalassemia is a blood disorder that affects hemoglobin, the part of red blood cells that carries oxygen.[1] In transfusion-dependent disease, patients need regular transfusions to keep blood levels stable.[1]
What the trials measure
The main endpoint is the proportion of subjects achieving transfusion independence.[1] In this study, transfusion independence means a weighted average hemoglobin of at least 9.0 g/dL without any red blood cell transfusion for a continuous period of at least 12 months.[1]
The assessment of this outcome starts 60 days after the last red blood cell transfusion used for post-transplant support or standard care for beta-thalassemia.[1] This timing helps the researchers judge the effect of the treatment after the transfusion support period has ended.[1]
In simple terms, the trial is asking whether patients can keep a good enough blood level for a full year without needing transfusions.[1] That is why hemoglobin level and transfusion-free time are the key measures in this study.[1]
Trial summary
Only one trial is provided in the source data, and it is a Phase 2, interventional study with 9 planned participants.[1] The study is authorised and is being conducted in a multicenter setting.[1]
The intervention list also includes busulfan, granulocyte colony-stimulating factor product GRANOCYTE, and plerixafor, but the source only lists these as study drugs and does not explain them in detail.[1] The main research question remains whether the gene therapy can reduce or remove the need for transfusions in beta-thalassemia.[1]
Below is a short summary of the trial information from the source data.[1]
| Trial ID | Title | Phase | Condition | Status | Enrollment |
|---|---|---|---|---|---|
| 2025-522160-32-00 | Single-arm, open-label, multicenter, single-dose study of gene therapy using autologous CD34+ hematopoietic stem cells transduced with the GLOBE lentiviral vector | Phase 2 | Transfusion-dependent beta-thalassemia | Authorised | 9 |
Important patient terms
Interventional study means the research team gives a treatment and then measures the results.[1]
Open label means there is no blinding, so everyone knows which treatment is being used.[1]
Multicenter means the study is being done at more than one hospital or research site.[1]
Single-dose means the treatment is given one time as part of the study plan.[1]
Transfusion independence means not needing red blood cell transfusions for a set period while keeping blood levels high enough.[1]
